Pharmaceutical giant AbbVie has made its entry into the obesity treatment market by acquiring an upfront payment of $350 million from biotech firm Gubra for its amylin-based drug. This marks a significant development in the highly competitive field, which has long been a coveted area of research in the pharmaceutical industry.
Source: https://endpts.com/abbvie-finally-enters-obesity-race-with-350m-upfront-for-gubras-amylin